If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Aptar Pharma’s Ophthalmic Squeeze Dispenser – Innovation based on experience

    • Aptar Pharma

    Preservatives in eye care products often cause discomfort or even serious side effects. With the Ophthalmic Squeeze Dispenser (OSD), Aptar Pharma has developed an entirely new system for the application of unpreserved ophthalmic formulations. The OSD comes without any debatable additives. It is a purely mechanical system which reliably avoids any microbiological contamination. At the same time it is easy and intuitive to handle and has significantly changed the eye care market.

    Although the discussion about the use of preservatives is still somewhat controversial, clinical evidence suggests that patients benefit from unpreserved eye drops especially in chronic conditions. During long-term treatment of diseases like dry-eye or glaucoma, preservatives in eye drops may worsen symptoms. Science has shown that the risks for patients experiencing severe local side effects increases significantly with the use of preserved ophthalmic medications. The experience of side effects when using eye drops as well as inconvenient handling may cause poor compliance.

    Recognizing the trend towards preservative-free topical drugs, Aptar Pharma in 2011 launched the Ophthalmic Squeeze Dispenser (OSD), an innovative multi-dose eyedropper for unpreserved ophthalmic preparations. In the few years since then some 70 commercial references have become available on markets worldwide utilizing this patient-friendly technology. The key advantage of this technology certainly is that it allows maintaining microbiological integrity of unpreserved formulations thanks to a proprietary dispensing system. The system relies on pure mechanical measures to ensure microbial integrity of the complete system during storage and when in use. The OSD offers also a wide range of settings to meet the requirements of various ophthalmic formulations.

    The microbiological safety of the OSD is qualified with the industry’s most challenging test procedures. Pharmaceutical manufacturers are consequently able to claim competitive storage and in-use periods. Patients and consumers also appreciate how convenient and intuitive it is to use the OSD. No particular instructions are required, the intuitive handling supports patient adherence.

    Aptar Pharma’s Ophthalmic Squeeze Dispenser (OSD) will be highlighted during the upcoming Pharmapack Europe event from February 10-11, 2016. Pharmapack is the biggest European exhibition for Drug Delivery Systems.
    During the event, Aptar Pharma will showcase the advantages of our innovative multi-dose eyedropper for unpreserved formulations with its microbial integrity and convenience. The following product showcase, with a short overview about the OSD, will be published during Pharmapack via “The Medicine Maker”.

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Lars Hoffmann
    • Product Info
    • English
    • Created 30 Jan 2016
    • Modified 30 Jan 2016
    • Hits 3342